jilibet online games

jilibet online games Super héros made in NigeriaContent warning: The following story contains mentions of sexual assault, including rape. Please proceed with caution and care. If you require support, there are resources available. On Thursday, the International Criminal Court (ICC) issued arrest warrants for Israeli prime minister Benjamin Nentayahu and defence minister Yoav Gallant. The ICC found that there was a reasonable probability that both Netanyahu and Gallant engaged in war crimes against the Palestinian people between October 8, 2023 and May 20, 2024, when the indictment was filed by ICC prosecutors. “The Chamber considered that there are reasonable grounds to believe that both individuals intentionally and knowingly deprived the civilian population in Gaza of objects indispensable to their survival, including food, water, and medicine and medical supplies, as well as fuel and electricity, from at least 8 October 2023 to 20 May 2024,” a statement on the ICC’s website about the arrest warrants reads. Israel began an invasion of Palestinian territory in Gaza after the terrorist group Hamas launched an attack against Israel on October 7, 2023 that killed over 1,200 civilians and saw the group take hostages, some of whom are still held in captivity. A report published by the UN earlier this summer found that over 40,000 Palestinians had lost their lives in the conflict up to that point, the majority of the casualties being women and children. The ICC found that Netanyahu and Gallant had impeded access to humanitarian aid, and did not do all within their power to ensure that relief was provided to Palestinians. “The (ICC) found that their conduct led to the disruption of the ability of humanitarian organisations to provide food and other essential goods to the population in need in Gaza. The aforementioned restrictions together with cutting off electricity and reducing fuel supply also had a severe impact on the availability of water in Gaza and the ability of hospitals to provide medical care,” the ICC statement goes on to read. The ICC has found reasonable grounds to believe that Netanyahu and Gallant used the tactic of starvation as a method of warfare against the Palestinian people, an act for which the court believes they may be criminally liable. The ICC did not find, however, that there were reasonable grounds to arrest Netanyahu and Gallant for the war crime of extermination, but did find reasonable grounds to arrest them for the crime of murder against Palestinian civilians. The ICC report concludes: “Finally, the Chamber assessed that there are reasonable grounds to believe that Mr Netanyahu and Mr Gallant bear criminal responsibility as civilian superiors for the war crime of intentionally directing attacks against the civilian population of Gaza. In this regard, the Chamber found that the material provided by the Prosecution only allowed it to make findings on two incidents that qualified as attacks that were intentionally directed against civilians. Reasonable grounds to believe exist that Mr Netanyahu and Mr Gallant, despite having measures available to them to prevent or repress the commission of crimes or ensure the submittal of the matter to the competent authorities, failed to do so.” ICC warrant also issued for Hamas chief The ICC also issued a warrant for the arrest of Mohammed Diab Ibrahim Al-Masri also known as “Dief” for war crimes and crimes against humanity. The court found that there were reasonable grounds to suspect that Deif had engaged in war crimes related to the October 7 attack because Hamas targeted civilians. The court further found that there were reasonable grounds to suspect that the hostages that were being detained by Hamas and its allies were being subjected to gender-based violence, including rape. “On the basis of the material presented, the Chamber found reasonable grounds to believe that the crimes of torture as a crime against humanity and war crime, rape and other forms of sexual violence as crimes against humanity and war crimes, cruel treatment as a war crime, and outrages upon personal dignity as a war crime were committed against these persons during the relevant period,” the ICC statement on Deif reads . Israel announced earlier this summer that they suspect the Deif had in fact been killed in an airstrike . Reactions to arrest warrants At a media event on Thursday, Prime Minister Justin Trudeau said that the country would abide by the rulings of the ICC. The implication of this being that should Netanyahu, Gallant, Deif, or any other individual subject to an arrest warrant by the ICC would be detained should they step on Canadian soil. Individuals and organizations that have opposed Israel’s attack against Palestinian civilians reacted positively to the news of the arrest warrants. “This is an important moment. Canada has chosen to do the right thing. We must continue to do the right thing. We must continue to uphold international law. We must not equivocate when it comes to upholding the international rules based order,” reads a statement from the National Council of Canadian Muslims. Israel rejected the findings of the court as “antisemitic,” as did Israel’s strongest ally, the US. The US is not a member of the ICC and is not bound by its rulings. The US national security council released the following statement: “The United States has been clear that the ICC does not have jurisdiction over this matter. In coordination with partners, including Israel, we are discussing next steps.” Support rabble today! We’re so glad you stopped by! Thanks for consuming rabble content this year. rabble.ca is 100% reader and donor funded, so as an avid reader of our content, we hope you will consider gifting rabble with a donation during our summer fundraiser today. Nick Seebruch, editor Whether it be a one-time donation or a small monthly contribution, your support is critical to keep rabble writers producing the work you’ve come to rely on as a part of a healthy media diet. Become a rabble rouser — donate to rabble.ca today. Nick Seebruch, editor Support rabble.caEx-Maryland Governor Larry Hogan shares video of mysterious drones, echoes calls for federal action (Picture credit: X) Reports of mysterious drone sightings across several states, including New Jersey, Maryland, and New York, have sparked growing concern among residents and lawmakers. As per The Guardian, the sightings have even been reported near sensitive areas such as military installations and critical infrastructure. However, the phenomenon remains unexplained, prompting calls for greater federal action and transparency. Former Maryland Governor Larry Hogan shared footage of large drones flying above his residence in Davidsonville, Maryland, just 25 miles from Washington, DC. Hogan, who observed the activity for 45 minutes, criticised the federal response, stating, “Neither the White House , the military, the FBI, nor Homeland Security has any idea what they are, where they came from, or who is controlling them and that is unacceptable.” Similarly, New Jersey Governor Phil Murphy urged President Joe Biden to prioritise the investigation, citing growing frustration over the lack of answers. In a letter to the White House, Murphy wrote, “The continued reporting of UAS (unmanned aircraft systems) activity has raised more questions than answers and prompted an outcropping of conspiracy theories.” The sightings have included reports of car-sized drones flying in groups over areas such as Naval Weapons Station Earle in New Jersey, where authorities confirmed multiple incursions. The Pentagon and FBI have ruled out foreign involvement, stating there is no evidence to suggest the drones pose a direct threat to public safety or national security, reported the Guardian. However, critics have slammed the federal response as inadequate. Hogan expressed frustration at the “dismissive attitude” of authorities, stating the government has the technology to trace the drones’ origins but has failed to act decisively. The FBI, leading the investigation, has received over 3,000 public tips but has yet to determine the source of the incursions. Officials noted that many sightings, upon analysis, appeared to involve lawfully operated manned aircraft. Still, the public and lawmakers demand more concrete answers, fearing potential vulnerabilities to critical infrastructure. While some lawmakers advocate for shooting down the drones for analysis, concerns about debris in densely populated areas have stalled such actions. The Pentagon insists that base commanders have the authority to act if the drones pose a threat, but no such incidents have been reported thus far.

OTTAWA — The federal government has introduced a stand-alone bill to implement the proposed GST holiday, hours after the NDP threatened to not pass the legislation if it was linked to a $250 rebate for working Canadians. The bill would give people a two-month GST exemption on items like premade food at grocery stores, children's clothes, toys, some alcoholic beverages and other holiday season staples. The Liberals had planned to also include legislation that would offer $250 benefit cheques for people who earned a working income up to $150,000 last year. Earlier today, NDP Leader Jagmeet Singh said his party would only support legislation to implement the GST break. He said the rebate plan needs to be fixed to include fully retired seniors and people who rely on disability benefits. The bill to implement the GST break is now expected to come to a vote on Thursday. This report by The Canadian Press was first published Nov. 27, 2024. David Baxter, The Canadian PressTHE first new treatment for asthma attacks in 50 years has been developed and could be "game-changing" for millions of people with the condition. Asthma attacks and chronic obstructive pulmonary disease (COPD) flare-ups - also known as exacerbations - can be deadly. Advertisement 3 Four people with asthma and 85 people with COPD die every day in the UK - the new treatment has been labelled "game-changing" Credit: Getty 3 Asthma attacks and COPD flare-ups are currently treated with steroid tablets Credit: Getty Four people with asthma and 85 people with COPD die every day in the UK, according to official figures - with someone having an asthma attack every 10 seconds. People with the conditions are currently treated with steroid tablets. But now an injection has been shown to be more effective, reducing the need for further treatment by 30 per cent. Researchers say their findings, published in The Lancet Respiratory Medicine, could be "game-changing" for millions of people with asthma and COPD around the world. Advertisement Read more on winter illnesses BUG BEAR Grim winter virus takes hold as killer lung infection targets under-5s SICK OF IT Grim warning as norovirus cases surge by 40% in weeks amid 'tripledemic threat' Lead investigator of the trial Professor Mona Bafadhel from King’s College London said: “This could be a game-changer for people with asthma and COPD. "Treatment for asthma and COPD exacerbations have not changed in fifty years despite causing 3.8 million deaths worldwide a year combined." The injection treat flare-ups called "eosinophilic exacerbation" and involve symptoms including wheezing, coughing and chest tightness due to inflammation resulting from high amounts of eosinophils, a type of white blood cell. Eosinophilic exacerbations make up to 30 per cent of COPD flare-ups and almost half of asthma attacks. Advertisement Most read in Health HORROR ORDEAL My GP gave anxiety meds for 'panic attacks' - my mum spotted the truth ON DEATH'S DOOR Teen left fighting for life with 'brain-swelling bug' after sharing a vape HORROR HEALTH BATTLE I lost parents to same deadly condition – then I was struck down by it WOOING POWER Testosterone does NOT make you sex-mad - but will still boost your love life Until now, steroid drugs have been the main medication. Steroids like prednisolone can reduce inflammation in the lungs but have severe side effects such as diabetes and osteoporosis. How to spot asthma in your child and signs of an asthma attack Many patients also " fail " treatment and need repeated courses of steroids, re-hospitalisation or die within 90 days. The study, led by scientists at King's College London and sponsored by the University of Oxford , looked at benralizamab, a drug already available that could be re-purposed in emergency settings. Advertisement The research team explained benralizamab is a monoclonal antibody which targets eosinophils to reduce lung inflammation It's currently used for the treatment of severe asthma. The trial found a single dose can be more effective when injected at the point of exacerbation compared to steroid tablets. Participants in the study, who were high risk of an asthma or COPD attack, were split into three groups by the research team. Advertisement One group received benralizamab injection and dummy tablets, another received standard of care (prednisolone 30mg daily for five days) and dummy injection and the third group receiving both benralizumab injection and standard of care. Neither the people in the study, or the study investigators knew which study arm or treatment they were given. After 28 days, respiratory symptoms of cough, wheeze, breathlessness and sputum were found to be better with benralizumab. After 90 days, there were four times fewer people in the benralizumab group that failed treatment compared to standard of care with prednisolone. Advertisement Treatment with the benralizumab injection took longer to fail, meaning fewer episodes to see a doctor or go to hospital. There was also an improvement in the quality of life for people with asthma and COPD. Prof Bafadhel said: “Benralizumab is a safe and effective drug already used to manage severe asthma. "We’ve used the drug in a different way – at the point of an exacerbation - to show that it’s more effective than steroid tablets which is the only treatment currently available. Advertisement “We hope these pivotal studies will change how asthma and COPD exacerbations are treated for the future , ultimately improving the health for over a billion people living with asthma and COPD across the world.” Geoffrey Pointing, 77, took part in the study Geoffrey, from Banbury, said when you're having a flare up, it's very difficult to tell anybody how you feel - you can hardly breathe. "Anything that takes that away and gives you back a normal life is what you want," he added. On the injections, he said: "It's fantastic. I didn't get any side effects like I used to with the steroid tablets. "I used to never sleep well the first night of taking steroids, but the first day on the study, I could sleep that first night, and I was able to carry on with my life without problems. "I want to add that I'm just grateful I took part and that the everyone involved in the ABRA study are trying to give me a better life.” Dr Sanjay Ramakrishnan, Clinical Senior Lecturer at the University of Western Australia, who is the first author of the ABRA trial and started the work while at the University of Oxford, said: “Our study shows massive promise for asthma and COPD treatment. "COPD is the third leading cause of death worldwide but treatment for the condition is stuck in the 20th century. "We need to provide these patients with life-saving options before their time runs out. Advertisement Dr Samantha Walker, Director of Research and Innovation, at Asthma + Lung UK, added: “It’s great news for people with lung conditions that a potential alternative to giving steroid tablets has been found to treat asthma attacks and chronic obstructive pulmonary disease (COPD) exacerbations. "But it’s appalling that this is the first new treatment for those suffering from asthma and COPD attacks in 50 years, indicating how desperately underfunded lung health research is. Read more on the Scottish Sun LOOKING UP I'm a four-time world champ but my eyesight is going so I've made crucial change ISLE SAY Stunning home with panoramic views for sale for just £135k - but there's a catch “Every four minutes in the UK, someone dies from a lung condition. Thousands more live with the terror of struggling to breathe every day. With your help, we're fighting for more life-changing, life-saving research to transform the future for everyone living with breathing problems. Together, we’ll make sure that families everywhere never face a lung condition without the best treatment and care. “Our vision is a world where everyone has healthy lungs. We can only get there with your help.” Advertisement Side effects of steroids Steroid tablets can be lifesaving but can have side effects, particularly if you’re taking higher doses over a long period of time. Most of these side effects are unlikely with a short course of steroids, but they may happen if you keep needing short courses to deal with symptoms that keep coming back, or because you keep having asthma attacks. Some side effects may be noticeable straight away, such as stomach problems, or changes to your mood (feeling depressed, or feeling ‘high’ or manic). Others may only be noticeable after weeks or months, such as weight gain, or a puffy ‘moon’ face. These are unlikely with a short course of steroids but can happen with repeated courses. Some side effects may develop over time. You’re more at risk of side effects like steroid-induced diabetes, or osteoporosis or thin skin and bruising if you’ve been taking steroid tablets for a long period of time, or if you need several short courses of high dose steroids in a year. Some 93 per cent said they had at least one condition linked to taking oral corticosteroids long-term. Source: Asthma + Lung 3 Benralizumab is a safe and effective drug already used to manage severe asthma, but it's now been used in a different way Credit: Getty

Vicus Capital reduced its position in Amazon.com, Inc. ( NASDAQ:AMZN ) by 23.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,404 shares of the e-commerce giant’s stock after selling 5,909 shares during the period. Vicus Capital’s holdings in Amazon.com were worth $3,616,000 as of its most recent filing with the Securities and Exchange Commission (SEC). A number of other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Amazon.com by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 785,811,114 shares of the e-commerce giant’s stock valued at $141,744,609,000 after acquiring an additional 14,724,687 shares during the period. Capital Research Global Investors increased its position in shares of Amazon.com by 8.5% in the first quarter. Capital Research Global Investors now owns 86,982,857 shares of the e-commerce giant’s stock valued at $15,689,968,000 after buying an additional 6,810,145 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Amazon.com by 1.5% during the 2nd quarter. Legal & General Group Plc now owns 69,686,374 shares of the e-commerce giant’s stock worth $13,466,933,000 after buying an additional 1,042,177 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Amazon.com by 0.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 67,745,972 shares of the e-commerce giant’s stock valued at $13,091,909,000 after buying an additional 289,532 shares in the last quarter. Finally, Capital International Investors grew its stake in Amazon.com by 7.4% in the 1st quarter. Capital International Investors now owns 42,370,172 shares of the e-commerce giant’s stock valued at $7,642,732,000 after acquiring an additional 2,932,192 shares during the period. 72.20% of the stock is owned by hedge funds and other institutional investors. Amazon.com Trading Down 0.6 % NASDAQ:AMZN opened at $197.12 on Friday. The stock has a fifty day moving average price of $193.00 and a 200 day moving average price of $186.31. The company has a current ratio of 1.09, a quick ratio of 0.87 and a debt-to-equity ratio of 0.21. Amazon.com, Inc. has a 12-month low of $142.81 and a 12-month high of $215.90. The firm has a market cap of $2.07 trillion, a PE ratio of 42.21, a price-to-earnings-growth ratio of 1.33 and a beta of 1.14. Wall Street Analysts Forecast Growth AMZN has been the topic of several research analyst reports. Evercore ISI lifted their target price on shares of Amazon.com from $240.00 to $260.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Morgan Stanley increased their target price on Amazon.com from $210.00 to $230.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Wedbush boosted their price target on Amazon.com from $225.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Roth Mkm raised their price objective on Amazon.com from $210.00 to $215.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, Piper Sandler increased their target price on shares of Amazon.com from $215.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating, forty have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Amazon.com currently has an average rating of “Moderate Buy” and an average price target of $235.77. Get Our Latest Research Report on Amazon.com Insiders Place Their Bets In other news, Director Daniel P. Huttenlocher sold 1,237 shares of Amazon.com stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $199.06, for a total transaction of $246,237.22. Following the completion of the sale, the director now directly owns 24,912 shares of the company’s stock, valued at approximately $4,958,982.72. The trade was a 4.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website . Also, SVP David Zapolsky sold 2,190 shares of the stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $195.00, for a total value of $427,050.00. Following the completion of the transaction, the senior vice president now directly owns 62,420 shares in the company, valued at $12,171,900. This trade represents a 3.39 % decrease in their position. The disclosure for this sale can be found here . Insiders sold 6,011,423 shares of company stock worth $1,249,093,896 in the last 90 days. Corporate insiders own 10.80% of the company’s stock. Amazon.com Profile ( Free Report ) Amazon.com, Inc engages in the retail sale of consumer products, advertising, and subscriptions service through online and physical stores in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Echo, Ring, Blink, and eero; and develops and produces media content. Read More Five stocks we like better than Amazon.com 3 Warren Buffett Stocks to Buy Now Vertiv’s Cool Tech Makes Its Stock Red-Hot How to Plot Fibonacci Price Inflection Levels MarketBeat Week in Review – 11/18 – 11/22 How to Calculate Stock Profit 2 Finance Stocks With Competitive Advantages You Can’t Ignore Want to see what other hedge funds are holding AMZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amazon.com, Inc. ( NASDAQ:AMZN – Free Report ). Receive News & Ratings for Amazon.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amazon.com and related companies with MarketBeat.com's FREE daily email newsletter .Town centre police dispersal powers in operation after rise in antisocial behaviour

Palvella Therapeutics to debut on Nasdaq under the ticker symbol "PVLA" as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately $80.0 million of cash and cash equivalents, including proceeds from a PIPE financing co-led by BVF Partners, L.P. and Frazier Life Sciences Cash expected to fund operations into the second half of 2027, including through Phase 3 SELVA clinical trial of QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) and Phase 2 clinical trial in cutaneous venous malformations (cutaneous VMs) Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. QTORINTM rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous VMs WAYNE, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol "PVLA". Palvella will continue to be led by Wes Kaupinen, its Founder and Chief Executive Officer, and other members of the Palvella management team. The transaction was approved by Pieris stockholders at a special meeting held on December 11, 2024, and the transaction had been previously approved by Palvella stockholders. "With strong support from leading healthcare-dedicated investors, Palvella is well positioned to enter the public markets and pursue our vision of becoming the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases," said Mr. Kaupinen. "This transaction will enable us to accelerate late-stage development of QTORINTM rapamycin, our lead product candidate, for microcystic LMs and cutaneous VMs while also further advancing additional novel product candidates from our QTORINTM platform." Concurrent with the merger, Palvella completed a previously announced oversubscribed $78.9 million private placement co-led by BVF Partners, L.P., an existing investor, and Frazier Life Sciences, a new investor, and with participation from a syndicate of leading healthcare-dedicated investors. Additional new investors include Blue Owl Healthcare Opportunities, Nantahala Capital, DAFNA Capital Management, ADAR1 Capital Management, and a healthcare dedicated fund. Existing investors Samsara BioCapital, Petrichor, CAM Capital, Ligand Pharmaceuticals, Integrated Finance Group (an AscellaHealth partner company), BioAdvance, and Gore Range Capital also participated in the financing. Palvella's cash and cash equivalents of approximately $80.0 million is expected to fund operations into the second half of 2027, including through results from the SELVA Phase 3 clinical trial of QTORINTM rapamycin for the treatment of microcystic LMs and Phase 2 clinical trial of QTORINTM rapamycin in cutaneous VMs. Palvella's research team developed QTORINTM, a patented and versatile platform designed to generate novel topical therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of serious, rare genetic skin diseases. Well-accepted mechanisms of action of rapamycin and other therapeutic agents represent potential therapies for rare genetic skin diseases. However, the adverse event profile of those agents through systemic exposure poses significant barriers to patient adoption. Palvella's QTORINTM product candidates are designed for targeted, localized delivery of therapeutic agents to pathogenic tissue of interest while minimizing systemic absorption and thereby reducing the risk of unwanted adverse events associated with systemic therapy. Palvella's lead product candidate QTORINTM rapamycin is a novel, patented 3.9% rapamycin anhydrous gel currently under development for the treatment of microcystic LMs, cutaneous VMs, and other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway. QTORINTM rapamycin has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for microcystic LMs and is the recent recipient of up to a $2.6 million FDA Orphan Products Grant. QTORINTM rapamycin has also received Fast Track Designation for venous malformations. QTORINTM rapamycin is protected by issued composition patents covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S., Japan, Australia, China and Israel and pending patent applications broadly covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S. and other countries. In the third quarter of 2024, Palvella initiated SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORINTM rapamycin administered once daily for the treatment of microcystic LMs. The primary efficacy endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment (mLM-IGA) at week 24. The Phase 3 study is enrolling approximately 40 subjects, age six or older, at leading vascular anomaly centers across the U.S. Transaction Details Based on the final exchange ratio of approximately 0.30946 shares of Pieris common stock for each share of Palvella common stock, at the closing of the merger, there are approximately 13.95 million shares of the combined company's common stock outstanding on a diluted basis, with prior Pieris stockholders owning approximately 11% on a diluted basis and prior Palvella stockholders (including investors in the private placement) holding approximately 89% of the combined company's outstanding common stock on a diluted basis. In connection with the closing of the merger, Pieris issued a non-transferable contingent value right (CVR) to Pieris shareholders of record immediately prior to the closing, which does not include the former holders of shares of Palvella or the private financing investors. Holders of the CVR will be entitled to receive payments from proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals, in addition to other potential licensing agreements involving certain of Pieris' legacy assets, as well as certain potential payments related to historical research and development tax credits, which may or may not be realized. TD Cowen served as lead placement agent and Cantor served as a placement agent for Palvella's concurrent financing. Troutman Pepper Hamilton Sanders LLP served as legal counsel to Palvella. Cooley LLP served as legal counsel to the placement agents. Stifel served as the exclusive financial advisor to Pieris and Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. served as legal counsel to Pieris. About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway. The disease is characterized by malformed lymphatic vessels that protrude through the skin and persistently leak lymph fluid (lymphorrhea) and bleed, often leading to recurrent serious infections and cellulitis that can cause hospitalization. The natural history of microcystic LMs are persistent and progressive without spontaneous resolution, with symptoms generally worsening during life, including increases in the number and size of malformed vessels that lead to complications and lifetime morbidity. There are currently no FDA-approved treatments for the estimated more than 30,000 diagnosed patients with microcystic LMs in the United States. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics PVLA is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORINTM platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella's lead product candidate, QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin), is currently in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase 2 trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow the Company on LinkedIn. QTORINTM rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella and Pieris, as well as assumptions made by, and information currently available to, management of Palvella and Pieris. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, the sufficiency of the combined company's capital resources; the combined company's cash runway; the expected timing of the closing of the proposed transactions; statements regarding the potential of, and expectations regarding, Palvella's programs, including QTORINTM rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity; the expected timing of initiating, as well as the design of Palvella's Phase 2 clinical trial of QTORINTM rapamycin in cutaneous venous malformations. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the limited operating history of each company; the significant net losses incurred since inception; the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella's product candidates, including QTORINTM rapamycin; the outcome of early clinical trials for Palvella's product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella's limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella's current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of the global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella and Pieris to protect their respective intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Pieris' most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, as well as the registration statement on Form S-4 filed with the SEC by Pieris in connection with the merger. Palvella and Pieris can give no assurance that the conditions to the proposed transactions will be satisfied. Except as required by applicable law, Palvella and Pieris undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. Palvella Therapeutics Contact Information Investors Wesley H. Kaupinen Founder and CEO, Palvella Therapeutics wes.kaupinen@palvellatx.com Media Stephanie Jacobson Managing Director, Argot Partners palvella@argotpartners.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.On Saturday at the legislature,the Edmonton Coalition on Housing and Homelessness along with participants, were calling on the provincial and federal governments to support more social housing in the city. “We are trying to draw attention to the catastrophe of homelessness, that’s utterly unnecessary, we’ve allowed homelessness to grow in this city and in this country by failing to build the housing that people that can’t afford the open market need,” said Jim Gurnett, spokesperson for Edmonton Coalition on Housing and Homelessness. The event also encouraging participants to cover themselves with blankets and tarps in quote. “To show what life is like for the 4000 plus homeless people in the city,” said Gurnett. Despite not intentionally planning to advocate on a snowy Saturday, Gurnett says it demonstrates how winter can impact the city’s homeless population. “We can choose, I can go home from being cold out here for a couple of hours and I can warm up but there’s more than 4000 people that won’t be able to do that today,” said Gurnett. One participant we spoke to say, he has some friends who also experienced some stages of homelessness. “I’ve learned with people just, what the solutions are and the answer is not to funnel more money in the capital accumulation,” said Ryan Kafara, Sociology and History Lecturer at University of Alberta. “We know, there’s more that needs to be done,” said Jason Nixon, Alberta Seniors Community and Social Services Minister. The Alberta government announced Friday, November 22nd, that they would be investing to boost the development of affordable housing in the province. “I am pleased to announce that the Alberta Affordable Housing Partnership Program is opening for the next round of application, with up to 150 million available in funding to support new affordable housing projects in our province,” said Nixon. However, Gurnett isn’t satisfied with the action of the UCP stating it isn’t really enough to address the growing demand for housing. “The amount that they’re investing in social housing isn’t a tenth of what they need to be investing,” said Gurnett. About 60 people attended the event with a donation drive for blankets, tarps and wagons, that were distributed once the event was over.State lives in ‘woke’ past

NEW YORK (AP) — Stocks wavered in afternoon trading on Wall Street Monday at the start of a holiday-shortened week. The S&P 500 rose 0.4%. A handful of technology companies helped support the gains. The Dow Jones Industrial Average slipped 63 points, or 0.2% as of 1:18 p.m. Eastern time. The tech-heavy Nasdaq composite rose 0.7%. Semiconductor giant Nvidia, whose enormous valuation gives it an outsize influence on indexes, rose 3%. Broadcom jumped 5.2% to also help support the broader market. Japanese automakers Honda Motor and Nissan said they are talking about combining in a deal that might also include Mitsubishi Motors. Honda rose 3.8% and Nissan rose 1.6% in Tokyo. Eli Lilly rose 3% after announcing that regulators approved Zepbound as the first and only prescription medicine for adults with sleep apnea. Department store Nordstrom fell 1.7% after it agreed to be taken private by Nordstrom family members and a Mexican retail group in a $6.25 billion deal. The Conference Board said that consumer confidence slipped in December. Its consumer confidence index fell back to 104.7 from 112.8 in November. Wall Street was expecting a reading of 113.8. The unexpectedly weak consumer confidence update follows several generally strong economic reports last week. One report showed the overall economy grew at a 3.1% annualized rate during the summer, faster than earlier thought. The latest report on unemployment benefit applications showed that the job market remains solid. A report on Friday said a measure of inflation the Federal Reserve likes to use was slightly lower last month than economists expected. Worries about inflation edging higher again had been weighing on Wall Street and the Fed. The central bank just delivered its third cut to interest rates this year, but inflation has been hovering stubbornly above its target of 2%. It has signaled that it could deliver fewer cuts to interest rates next year than it earlier anticipated because of concerns over inflation. Expectations for more interest rate cuts have helped drive a 24% gain for the S&P 500 in 2024. That drive included 57 all-time highs this year. Inflation concerns have added to uncertainties heading into 2025, which include the labor market's path ahead and shifting economic policies under an incoming President Donald Trump. "Put simply, much of the strong market performance prior to last week was driven by expectations that a best-case scenario was the base case for 2025," said Brent Schutte, chief investment officer at Northwestern Mutual Wealth Management Company Treasury yields edged higher in the bond market. The yield on the 10-year Treasury rose to 4.58% from 4.53% late Friday. European markets were mostly lower, while markets in Asia gained ground. Wall Street has several other economic reports to look forward to this week. On Tuesday, the U.S. will release its November report for sales of newly constructed homes. A weekly update on unemployment benefits is expected on Thursday. Markets in the U.S. will close early on Tuesday for Christmas Eve and will remain closed on Wednesday for Christmas.

Bengals quarterback Joe Burrow came out of Monday night’s win over the Cowboys with a knee issue, but it won’t impact his availability for Sunday’s game against the Titans. Burrow was limited in practice on Wednesday and Thursday before returning to full practice participation. Burrow has no injury designation, which leaves him on track to start in Tennessee. Left tackle Orlando Brown Jr. (fibula), defensive tackle Sheldon Rankins (illness), and linebacker Joe Bachie (groin) all missed practice every day this week and they have been ruled out for Sunday. Wide receiver Charlie Jones (groin) returned for a limited practice on Friday and he is the only Bengals player with an injury designation.

TikToker arrested after filming herself getting ready to steal from Target, police sayBy MICHAEL R. SISAK and JENNIFER PELTZ NEW YORK (AP) — President-elect Donald Trump’s lawyers urged a judge again Friday to throw out his hush money conviction, balking at the prosecution’s suggestion of preserving the verdict by treating the case the way some courts do when a defendant dies. They called the idea “absurd.” Related Articles National Politics | Trump wants to turn the clock on daylight saving time National Politics | Ruling by a conservative Supreme Court could help blue states resist Trump policies National Politics | A nonprofit leader, a social worker: Here are the stories of the people on Biden’s clemency list National Politics | Nancy Pelosi hospitalized after she ‘sustained an injury’ on official trip to Luxembourg National Politics | Veteran Daniel Penny, acquitted in NYC subway chokehold, will join Trump’s suite at football game The Manhattan district attorney’s office is asking Judge Juan M. Merchan to “pretend as if one of the assassination attempts against President Trump had been successful,” Trump’s lawyers wrote in a blistering 23-page response. In court papers made public Tuesday, District Attorney Alvin Bragg’s office proposed an array of options for keeping the historic conviction on the books after Trump’s lawyers filed paperwork earlier this month asking for the case to be dismissed. They include freezing the case until Trump leaves office in 2029, agreeing that any future sentence won’t include jail time, or closing the case by noting he was convicted but that he wasn’t sentenced and his appeal wasn’t resolved because of presidential immunity. Trump lawyers Todd Blanche and Emil Bove reiterated Friday their position that the only acceptable option is overturning his conviction and dismissing his indictment, writing that anything less will interfere with the transition process and his ability to lead the country. The Manhattan district attorney’s office declined comment. It’s unclear how soon Merchan will decide. He could grant Trump’s request for dismissal, go with one of the prosecution’s suggestions, wait until a federal appeals court rules on Trump’s parallel effort to get the case moved out of state court, or choose some other option. In their response Friday, Blanche and Bove ripped each of the prosecution’s suggestions. Halting the case until Trump leaves office would force the incoming president to govern while facing the “ongoing threat” that he’ll be sentenced to imprisonment, fines or other punishment as soon as his term ends, Blanche and Bove wrote. Trump, a Republican, takes office Jan. 20. “To be clear, President Trump will never deviate from the public interest in response to these thuggish tactics,” the defense lawyers wrote. “However, the threat itself is unconstitutional.” The prosecution’s suggestion that Merchan could mitigate those concerns by promising not to sentence Trump to jail time on presidential immunity grounds is also a non-starter, Blanche and Bove wrote. The immunity statute requires dropping the case, not merely limiting sentencing options, they argued. Blanche and Bove, both of whom Trump has tabbed for high-ranking Justice Department positions, expressed outrage at the prosecution’s novel suggestion that Merchan borrow from Alabama and other states and treat the case as if Trump had died. Blanche and Bove accused prosecutors of ignoring New York precedent and attempting to “fabricate” a solution “based on an extremely troubling and irresponsible analogy between President Trump” who survived assassination attempts in Pennsylvania in July and Florida in September “and a hypothetical dead defendant.” Such an option normally comes into play when a defendant dies after being convicted but before appeals are exhausted. It is unclear whether it is viable under New York law, but prosecutors suggested that Merchan could innovate in what’s already a unique case. “This remedy would prevent defendant from being burdened during his presidency by an ongoing criminal proceeding,” prosecutors wrote in their filing this week. But at the same time, it wouldn’t “precipitously discard” the “meaningful fact that defendant was indicted and found guilty by a jury of his peers.” Prosecutors acknowledged that “presidential immunity requires accommodation” during Trump’s impending return to the White House but argued that his election to a second term should not upend the jury’s verdict, which came when he was out of office. Longstanding Justice Department policy says sitting presidents cannot face criminal prosecution . Other world leaders don’t enjoy the same protection. For example, Israeli Prime Minister Benjamin Netanyahu is on trial on corruption charges even as he leads that nation’s wars in Lebanon and Gaza . Trump has been fighting for months to reverse his May 30 conviction on 34 counts of falsifying business records . Prosecutors said he fudged the documents to conceal a $130,000 payment to porn actor Stormy Daniels to suppress her claim that they had sex a decade earlier, which Trump denies. In their filing Friday, Trump’s lawyers citing a social media post in which Sen. John Fetterman used profane language to criticize Trump’s hush money prosecution. The Pennsylvania Democrat suggested that Trump deserved a pardon, comparing his case to that of President Joe Biden’s pardoned son Hunter Biden, who had been convicted of tax and gun charges . “Weaponizing the judiciary for blatant, partisan gain diminishes the collective faith in our institutions and sows further division,” Fetterman wrote Wednesday on Truth Social. Trump’s hush money conviction was in state court, meaning a presidential pardon — issued by Biden or himself when he takes office — would not apply to the case. Presidential pardons only apply to federal crimes. Since the election, special counsel Jack Smith has ended his two federal cases , which pertained to Trump’s efforts to overturn his 2020 election loss and allegations that he hoarded classified documents at his Mar-a-Lago estate. A separate state election interference case in Fulton County, Georgia, is largely on hold. Trump denies wrongdoing in all. Trump had been scheduled for sentencing in the hush money case in late November. But following Trump’s Nov. 5 election victory, Merchan halted proceedings and indefinitely postponed the former and future president’s sentencing so the defense and prosecution could weigh in on the future of the case. Merchan also delayed a decision on Trump’s prior bid to dismiss the case on immunity grounds. A dismissal would erase Trump’s conviction, sparing him the cloud of a criminal record and possible prison sentence. Trump is the first former president to be convicted of a crime and the first convicted criminal to be elected to the office.

The Manhattan district attorney’s office is asking Judge Juan M. Merchan to “pretend as if one of the assassination attempts against President Trump had been successful,” Trump’s lawyers wrote in a blistering 23-page response. Click to share on Facebook (Opens in new window) Click to share on X (Opens in new window) Most Popular Distraught man tried to get police to shoot him, ultimately leading to shots fired in both directions Distraught man tried to get police to shoot him, ultimately leading to shots fired in both directions Youngkin wants to pull Virginia funding from ‘sanctuary cities’ Youngkin wants to pull Virginia funding from ‘sanctuary cities’ Isle of Wight teacher arrested on child porn charges Isle of Wight teacher arrested on child porn charges Woman dies, driver injured in James City County crash Woman dies, driver injured in James City County crash Large drone spotted in Virginia Beach near military installation Large drone spotted in Virginia Beach near military installation Colonial Williamsburg’s Grand Illumination has echoes across the US Colonial Williamsburg's Grand Illumination has echoes across the US Wrong-way driver on I-64 arrested, charged with driving under the influence Wrong-way driver on I-64 arrested, charged with driving under the influence David Teel: Pure genius or desperate folly? UNC welcomes Bill Belichick. David Teel: Pure genius or desperate folly? UNC welcomes Bill Belichick. Head of the Federal Aviation Administration to resign, allowing Trump to pick his successor Head of the Federal Aviation Administration to resign, allowing Trump to pick his successor The Navy’s fighter pilots fly at the extremes. Their brains may suffer. The Navy’s fighter pilots fly at the extremes. Their brains may suffer. Trending Nationally President Joe Biden commutes sentences for two of Chicago area’s most notorious fraudsters Drone sightings reach Pennsylvania; Monroe County officials ask residents to report them to 911 How pythons and other invasive species may have spread farther in Florida due to hurricanes Snowboarder seriously injured in 47-foot fall from chairlift at Keystone Resort ‘Enron CEO’ Connor Gaydos hit in the face with pie in New York City

CAPE CORAL, Fla. -- A 22-year-old social media influencer on TikTok with nearly 300,000 followers has been arrested after using fake barcodes to steal from Target and filming herself getting ready before the alleged theft, police say. The Cape Coral Police Department in Florida responded to a Target branch located at 1890 NE Pine Island Road in Cape Coral last Wednesday regarding a past retail theft that occurred on Oct. 30, according to a statement from the Cape Coral Police Department. "Loss Prevention at Target stated that on October 30, 2024, an unknown female entered the store and selected items listed for sale," police said. "Once at the self-checkout register, the female suspect did not scan the items' barcodes, instead scanning a false barcode with cheaper prices." In total, 16 items of miscellaneous household goods and clothing were stolen with a total retail value of $500.32, which was verified by officers via Target's security cameras. In an attempt to help identify the suspect through public assistance, the Cape Coral Police Department's Facebook and Instagram accounts posted the female's picture, describing her as appearing to be "approximately 20-35 years old, had long black hair, and was wearing a tan shirt, tan pants, and glasses." An anonymous caller who saw the post on social media subsequently contacted the police and gave the possible identification for the suspect as Marlena Velez and informed them of her social media profiles. "Officers then found Marlena's TikTok account, which documents her getting ready on October 30, 2024, in the same outfit and glasses and going to Target," police said. "Marlena documents herself picking out items inside the store and placing them in her car after exiting the store. Marlena appears to be a content creator with almost 300,000 followers." Velez has since been arrested and taken to the Lee County Jail and charged with petit theft of less than $750. The investigation is currently ongoing.Can Trump Use the Military to Arrest Immigrants?

CAPE CORAL, Fla. -- A 22-year-old social media influencer on TikTok with nearly 300,000 followers has been arrested after using fake barcodes to steal from Target and filming herself getting ready before the alleged theft, police say. The Cape Coral Police Department in Florida responded to a Target branch located at 1890 NE Pine Island Road in Cape Coral last Wednesday regarding a past retail theft that occurred on Oct. 30, according to a statement from the Cape Coral Police Department. "Loss Prevention at Target stated that on October 30, 2024, an unknown female entered the store and selected items listed for sale," police said. "Once at the self-checkout register, the female suspect did not scan the items' barcodes, instead scanning a false barcode with cheaper prices." In total, 16 items of miscellaneous household goods and clothing were stolen with a total retail value of $500.32, which was verified by officers via Target's security cameras. In an attempt to help identify the suspect through public assistance, the Cape Coral Police Department's Facebook and Instagram accounts posted the female's picture, describing her as appearing to be "approximately 20-35 years old, had long black hair, and was wearing a tan shirt, tan pants, and glasses." An anonymous caller who saw the post on social media subsequently contacted the police and gave the possible identification for the suspect as Marlena Velez and informed them of her social media profiles. "Officers then found Marlena's TikTok account, which documents her getting ready on October 30, 2024, in the same outfit and glasses and going to Target," police said. "Marlena documents herself picking out items inside the store and placing them in her car after exiting the store. Marlena appears to be a content creator with almost 300,000 followers." Velez has since been arrested and taken to the Lee County Jail and charged with petit theft of less than $750. The investigation is currently ongoing.

Saudi Arabia Is All Set To Construct The World’s Largest Sports Stadium

"If you do not want to die in the war," the Ukrainian government-backed hotline, "I Want To Live," proclaims in large letters on its homepage, then they are the ones to contact. Established for Russian soldiers to surrender and get themselves out of Moscow's ranks, the hotline is preparing for North Korean soldiers to reach out for the first time. The "I Want To Live" project isn't expecting a "massive" wave of messages or calls from North Korean soldiers, but is anticipating a few fighters drafted into front-line clashes to make contact, Vitalii, a spokesperson for the hotline, told Newsweek . None of the thousands of soldiers sent from North Korea to Russian soil have contacted the project yet, Vitalii said. South Korean, U.S. and Ukrainian intelligence have indicated that upward of 10,000 North Korean soldiers have been sent to the western Russian region of Kursk to support Moscow's war effort. Ukraine launched an offensive into the region in early August, andstill holds hundreds of square miles of Russian territory. Pyongyang's fighters are thought to be kitted out in Russian garb and have been taken into the Kremlin's existing military forces. Russia has not confirmed or denied the presence of North Korean troops in Kursk, but has signed a mutual defense pact with the secretive country's supreme leader, Kim Jong-un. Russian Preside nt Vladimir Putin said it was "entirely our own business" how to implement the defense agreement between Moscow and Pyongyang. North Korea has supplied a significant number of missiles and shipments of munitions to prop up the Kremlin's war effort. A South Korean intelligence official said earlier this week that Russia had provided air-defense equipment and "economic aid in various forms" to North Korea. U.S. Secretary of Defense Lloyd Austin said on Saturday that he expected to see North Korean soldiers "engaged in combat soon." The State Department confirmed in mid-November that North Korean soldiers were "engaging in combat operations with Russian forces" after undergoing training in how to use drones, artillery, and carry out "basic infantry operations." Ukraine's Defense Minister, Rustem Umerov, told South Korean media earlier this month that North Korean soldiers had been involved in "small-scale clashes" so far. The North Korean troops arrived in Russia at a moment when Moscow, like Kyiv, is searching for ways to backfill its military ranks in the face of eye-watering casualty counts. Russia has been steadily advancing in Ukraine's east, but has racked up a high number of casualties in the process, according to numbers coming out of Ukraine. The "I Want To Live" hotline was quick to launch a social media appeal in Korean more than a month ago. "We appeal to the fighters of the Korean People's Army who were sent to help the Putin regime," the hotline said in a post to messaging app Telegram, using the formal name for North Korea's army. "You should not die senselessly on foreign soil," the project wrote. "Do not repeat the fate of hundreds of thousands of Russian soldiers who will never return home!" Those who surrender to Ukrainian forces are promised shelter, hot meals and medical care for those who need it. "It does not matter how many soldiers Pyongyang sends to help Russia, it does not matter in which direction—Ukrainian prisoner of war camps are ready to accept soldiers of any nationality, religion and ideological views," the hotline said. Extracting each soldier from the fighting is a unique process, Vitalii said. "There are many factors and variables, so I cannot say exactly how we will do it," he said, "but the main thing is the safety of both the surrendered and our units that are being brought to the territory controlled by Ukraine." Each fighter who reaches out keeps up a constant link with the hotline, Vitalii said. A bespoke evacuation plan is then devised, taking into account the weather conditions, the landscape and which section of the hundreds of miles of front line the soldier is deployed to, he added. It's not yet clear whether North Korean fighters will be found along other sections of the front line. Andriy Kovalenko, an official with Ukraine's National Security and Defense Council, said earlier this week that an unspecified number of North Korean soldiers were "transferred to the border areas of the Belgorod region." Belgorod borders Kursk, sitting across from Ukraine's northeastern Kharkiv region. Newsweek could not independently verify this. The hotline is "monitoring" where North Korean forces end up, Vitalii said. "We have now made a video message to the North Korean military and developed leaflets that will be distributed at the front," he added. The project also has specialists who can communicate in Korean, Vitalii said. There are still big question marks over how well the North Korean soldiers, for whom this will be their first combat experience, will cope with warfare on the front lines in Europe. Officials and experts have pointed to likely problems with communication, slotting into the command structure of Russia's military, and morale. Pyongyang's fighters are "conditioned with unwavering loyalty to their leadership and a unique psychological resilience cultivated by the regime," Ji Hyun Park, a North Korean defector, now a senior fellow for human security at the Center for Asia Pacific Strategy, previously told Newsweek . It is designed to instill a willingness to sacrifice everything for the state, Park said. "However, this psychological preparation may not translate effectively into practical resilience in the type of active combat scenarios currently seen in Ukraine, where they would face modernized and highly capable opposition in unfamiliar territory," Park added. A group of North Korean defectors based in the South Korean capital said earlier this month that they handed over written instructions and audio messages for North Korean fighters on how to defect to Ukrainian officials in Seoul. Jang Se-yul, heading up the group, said Kyiv's military "could secure mass surrender and defection among North Korean soldiers if proactive psychological warfare is mobilized," according to South Korea's Yonhap news agency. Although the North Koreans may be unfamiliar with Russia's territory and weapons stockpiles, they probably will not need extensive training on the guns, rifles, mortars and other explosives Moscow uses against Ukraine, Ramon Pacheco Pardo, a professor of international relations at King's College London, previously told Newsweek . At least some of the thousands of fighters are thought to be "Storm Troops," or members of Pyongyang's special operations forces trained for infiltration and assassination. It is impossible to tell how well equipped they are for active conflict.

Nathan Cleary’s bizarre diet change secret stuns fansTeKnowledge is Driving the Future of AI in Nigeria and AfricaMMIS Inc. Celebrates Over Two Decades of Excellence in Custom Spice Blending and Packaging 12-23-2024 07:22 PM CET | Fashion, Lifestyle, Trends Press release from: Getnews MMIS Inc., a trusted leader in the food manufacturing industry, proudly marks over two decades of innovation and excellence in custom spice blending and packaging. With a steadfast commitment to quality and a reputation for meeting the evolving needs of its customers, MMIS continues to set the benchmark for custom spice solutions across North America. Since its inception in 2001, MMIS has specialized in blending spice formulas tailored to meet the unique requirements of its clients. The company's dedication to delivering consistent, high-quality products has been a driving force behind its success. From humble beginnings, MMIS has grown into a trusted partner for food manufacturers, offering a comprehensive range of services that include custom spice blending and packaging [ https://mmis.ca/custom-blending/ ], innovative packaging solutions, and unmatched customer service. A Commitment to Quality and Food Safety Central to MMIS's operations is its unwavering commitment to food safety and quality assurance. The company achieved Safe Quality Food (SQF) certification in 2017, a globally recognized standard that underscores its adherence to the highest levels of food safety. This milestone reflects MMIS's dedication to not only meeting but exceeding industry standards. In addition to its SQF certification, MMIS has expanded its capabilities to include certifications for Organic and Kosher products, enabling the company to cater to a broader range of consumer preferences. These certifications have positioned MMIS as a trusted source for high-quality, certified spice blends that meet the rigorous demands of today's health-conscious and ethically minded consumers. Innovation Through Clean Label Solutions As consumer preferences continue to shift toward transparency and natural ingredients, MMIS has been at the forefront of the clean label movement. The company's Mondo Pure line, introduced in 2018, is a testament to this commitment. This clean label product line is crafted to align with growing consumer demands for products free from artificial additives, ensuring that food manufacturers can deliver wholesome and flavorful offerings to their customers. The success of the Mondo Pure line highlights MMIS's ability to anticipate and adapt to market trends, reinforcing its reputation as an industry innovator. By combining traditional blending techniques with modern food science, MMIS continues to provide solutions that balance flavor, functionality, and consumer appeal. State-of-the-Art Facilities for a Sustainable Future In 2020, MMIS relocated its operations to a state-of-the-art facility in Barrie, Ontario. This new facility was designed with food safety and sustainability at its core, allowing MMIS to streamline its operations and reduce its environmental footprint. The move not only expanded the company's production capacity but also enhanced its ability to meet the diverse needs of its growing client base. The Barrie facility adheres to the strictest sanitation and safety regulations, ensuring that every product leaving the premises meets the highest standards of quality. This investment in advanced infrastructure underscores MMIS's commitment to fostering a sustainable future while maintaining its position as a leader in the spice blending and packaging industry. Supporting Food Manufacturers with Tailored Solutions One of MMIS's core strengths lies in its ability to deliver tailored spice solutions that address the specific needs of food manufacturers. Whether it's creating custom spice blends to achieve a unique flavor profile or developing innovative packaging solutions to enhance shelf appeal, MMIS works closely with its clients to ensure their success. The company's extensive experience and expertise enable it to serve a diverse range of industries, including meat processing, snack foods, and ready-to-eat meals. By providing personalized service and technical support, MMIS helps its clients stay competitive in an ever-changing market. A Legacy of Excellence and Innovation For over two decades, MMIS has been synonymous with quality, innovation, and customer satisfaction. Its journey from a regional supplier to a recognized leader in custom spice blending and packaging is a testament to its dedication and vision. The company's ability to adapt to industry trends and consistently deliver exceptional products has earned it the trust of countless food manufacturers across North America. As MMIS celebrates this significant milestone, it remains focused on the future. By continuing to invest in research, technology, and sustainable practices, the company is well-positioned to address the challenges and opportunities of the food manufacturing industry. MMIS's ongoing commitment to excellence ensures that it will remain a trusted partner for custom spice solutions for many years to come. About MMIS Inc. MMIS Inc. specializes in custom spice blending and packaging, serving the North American food manufacturing industry with innovative solutions and exceptional service. The company's operations are based out of its state-of-the-art facility in Barrie, Ontario. With a focus on quality, sustainability, and customer satisfaction, MMIS continues to set the standard for excellence in the spice blending and packaging sector. For more information, please contact: MMIS Inc. 151 King Street, Barrie, Ontario, L4N 6B5 Phone: 905-841-1717 Media Contact Company Name: MMIS Inc. Contact Person: George Email: Send Email [ http://www.universalpressrelease.com/?pr=mmis-inc-celebrates-over-two-decades-of-excellence-in-custom-spice-blending-and-packaging ] City: Barrie State: Ontario Country: Canada Website: https://mmis.ca/ This release was published on openPR.